Glakolens is developing a state-of-the-art non-invasive biosensor platform with proprietary technology that will enable continuous IOP monitoring for 24 hours. Our innovation (US Patent No: US10067075B2, additional PCT applications pending) is comprised of an electrically passive sensor embedded in a comfortable disposable soft contact lens, and a wearable electronic system to take non-contact measurements from the sensor and to store the data. The placement of the disposable contact lens sensor and the wearable electronic system are carried out by trained medical staff in the clinic. The patient wears the products for 24 hours and returns to the clinic the next day, where staff download the IOP data from the device and deliver the results to the ophthalmologists for evaluation. Armed with the information on the daily pattern and values of IOP, the ophthalmologists will be able to accurately evaluate the condition of the patient with a single test and rapidly devise a successful treatment algorithm to manage the progression of the disease and prevent vision loss. By enabling early diagnosis and monitoring of ocular hypertension and glaucoma conditions, our product will help to maintain the quality of life of the patients and reduce the vision loss induced substantial economic burden.
GlakoLens IOP sensor is based on the principle of resonant frequency shift of a metallic resonator with meta-material properties under mechanical stress. This is a novel approach to accurately monitor fluctuations in IOP by measuring changes in the geometry of a sensor placed on the cornea. The data is collected wirelessly by transmitting a very low power RF signal generated by a light-weight Holter-monitor-like device comprising an electronic circuit and a custom design wearable antenna.